Lipids, LXRs and prostate cancer: Are HDACs a new link?

Biochemical Pharmacology

Volumn 86, Issue 1, 2013, Pages 168-174

  Hoang, Jean Joseph ^a,b,c,d   Baron, Silvère ^a,b,c,d   Volle, David H ^a,b,c,d   Lobaccaro, Jean Marc A ^a,b,c,d   Trousson, Amalia ^a,b,c,d  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b CNRS   (France)

^c Faculté de Médecine   (France)

^d CRNH AUVERGNE   (France)

Author keywords

HDAC; Lipids; LXR; Prostate cancer

Indexed keywords

ANTIMETABOLITE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CHOLESTEROL; FATTY ACID; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITOR; INTERCALATING AGENT; LIPID; LIVER X RECEPTOR; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; EDIBLE OIL; ORPHAN NUCLEAR RECEPTOR;

BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; ENZYME ACTIVITY; FAT INTAKE; FATTY ACID METABOLISM; HOMEOSTASIS; HUMAN; NIEMANN PICK DISEASE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; ANIMAL; CELL PROLIFERATION; GENETIC TRANSCRIPTION; GENETICS; LIPID METABOLISM; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR;

ANIMALS; CELL PROLIFERATION; CHOLESTEROL; DIETARY FATS, UNSATURATED; HISTONE DEACETYLASES; HUMANS; LIPID METABOLISM; MALE; ORPHAN NUCLEAR RECEPTORS; PROSTATIC NEOPLASMS; TRANSCRIPTION, GENETIC;

EID: 84884335313     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.04.005     Document Type: Review

References (89)

1. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, et al. Human prostate cancer risk factors. Cancer 2004;101:2371-490. (Pubitemid 39505434)
2. Parkin DM, Muir CS. Cancer incidence in five continents. Comparability and quality of data. IARC Sci Publ 1992;(120):45-173.
3. Chua ME, Sio MC, Sorongon MC, Dy JS. Relationship of dietary intake of omega- 3 and omega-6 Fatty acids with risk of prostate cancer development: a metaanalysis of prospective studies and review of literature. Prostate Cancer 2012;2012:826254.
4. Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CC, et al. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 1993;85:1571-9. (Pubitemid 23304685)
5. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991;63:963-6.
6. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol 1927;8:519-30.
7. Medes G, Thomas A, Weinhouse S. Metabolism of neoplastic tissue, IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res 1953;13:27-9.
8. Beckers A, Organe S, Timmermans L, Scheys K, Peeters A, Brusselmans K, et al. Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res 2007;67:8180-7. (Pubitemid 47395154)
9. Brusselmans K, De Schrijver E, Verhoeven G, Swinnen JV. RNA interferencemediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res 2005;65:6719-25. (Pubitemid 41060709)
10. Swinnen JV, Brusselmans K, Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care 2006;9: 358-65. (Pubitemid 44101970)
11. Swinnen JV, Roskams T, Joniau S, Van Poppel H, Oyen R, Baert L, et al. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 2002;98:19-22. (Pubitemid 34113412)
12. Swinnen JV, Vanderhoydonc F, Elgamal AA, Eelen M, Vercaeren I, Joniau S, et al. Selective activation of the fatty acid synthesis pathway in human prostate cancer. Int J Cancer 2000;88:176-9.
13. Van de Sande T, De Schrijver E, Heyns W, Verhoeven G, Swinnen JV. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Res 2002;62:642-6. (Pubitemid 34126933)
14. Suburu J, Chen YQ. Lipids and prostate cancer. Prostaglandins Other Lipid Mediat 2012;98:1-10.
15. Minner S, Jessen B, Stiedenroth L, Burandt E, Kollermann J, Mirlacher M, et al. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res 2010;16:1553-60.
16. Furuta E, Pai SK, Zhan R, Bandyopadhyay S, Watabe M, Mo YY, et al. Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1. Cancer Res 2008;68:1003-11. (Pubitemid 351278386)
17. Huang WC, Li X, Liu J, Lin J, Chung LW. Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Mol Cancer Res 2012;10:133-42.
18. Brar SS, Corbin Z, Kennedy TP, Hemendinger R, Thornton L, Bommarius B, et al. NOX5 NAD(P)H oxidase regulates growth and apoptosis in DU 145 prostate cancer cells. Am J Physiol Cell Physiol 2003;285:C353-69. (Pubitemid 36917850)
19. White C. The occurence of cristals in tumors. J Pathol Bacteriol 1909;13:3-10.
20. Swyer GI. Post-natal growth changes in the human prostate. J Anat 1944;78:130-45.
21. Freeman MR, Solomon KR. Cholesterol and prostate cancer. J Cell Biochem 2004;91:54-69.
22. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
23. Roy M, Kung HJ ,Ghosh PM. Statins and prostate cancer: role of cholesterol inhibitionvs. prevention of small GTP-binding proteins. Am J Cancer Res 2011;1:542-61.
24. Grover VK, Valadez JG, Bowman AB, Cooper MK. Lipid modifications of Sonic hedgehog ligand dictate cellular reception and signal response. PLoS One 2011;6:e21353.
25. Bailey JM, Singh PK, Hollingsworth MA. Cancer metastasis facilitated by developmental pathways: sonic hedgehog, notch, and bone morphogenic proteins. J Cell Biochem 2007;102:829-39. (Pubitemid 350036923)
26. Gerber M. Omega-3 fatty acids and cancers: a systematic update review of epidemiological studies. Br J Nutr 2012;107(Suppl. 2):S228-39.
27. Hajjaji N, Bougnoux P. Selective sensitization of tumors to chemotherapy by marine-derived lipids: a reviewCancer Treat Rev 2012 [Epub ahead of print].
28. Bougnoux P, Germain E, Chajes V, Hubert B, Lhuillery C, Le Floch O, et al. Cytotoxic drugs efficacy correlates with adipose tissue docosahexaenoic acid level in locally advanced breast carcinoma. Br J Cancer 1999;79:1765-9. (Pubitemid 29132302)
29. Begin ME, Ells G, Horrobin DF. Polyunsaturated fatty acid-induced cytotoxicity against tumor cells and its relationship to lipid peroxidation. J Natl Cancer Inst 1988;80:188-94.
30. Das UN, Madhavi N, Kumar G S, Padma M, Sangeetha P. Can tumour cell drug resistance be reversed by essential fatty acids and their metabolites. Prostaglandins Leukot Essent Fatty Acids 1998;58:39-54. (Pubitemid 28053789)
31. Vibet S, Maheo K, Gore J, Dubois P, Bougnoux P, Chourpa I. Differential subcellular distribution of mitoxantrone in relation to chemosensitization in two human breast cancer cell lines. Drug Metab Dispos 2007;35:822-8. (Pubitemid 46641554)
32. Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 2006;126:789-99. (Pubitemid 44233630)
33. Janowski BA, Grogan MJ, Jones SA, Wisely GB, Kliewer SA, Corey EJ, et al. Structural requirements of ligands for the oxysterol Liver X Receptors LXRalpha and LXRbeta. Proc Natl Acad Sci U S A 1999;96:266-71. (Pubitemid 29036088)
34. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996;383:728-31. (Pubitemid 26360651)
35. Willy PJ, Umesono K, Ong ES, Evans RM, Heyman RA, Mangelsdorf DJ. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev 1995;9:1033-45.
36. Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 1995;377:454-7.
37. Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, et al. Ligandindependent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 1995;377:397-404.
38. Huuskonen J, Fielding PE, Fielding CJ. Role of p160 coactivator complex in the activation of liver X receptor. Arterioscler Thromb Vasc Biol 2004;24:703-8. (Pubitemid 38451607)
39. Oberkofler H, Schraml E, Krempler F, Patsch W. Potentiation of liver X receptor transcriptional activity by peroxisome-proliferator-activated receptor gamma co-activator 1 alpha. Biochem J 2003;371:89-96. (Pubitemid 36458082)
40. Viennois E, Pommier AJ, Mouzat K, Oumeddour A, El Hajjaji FZ, Dufour J, et al. Targeting Liver X Receptors in human health: deadlock or promising trail? Expert Opin Ther Targets 2011;15:219-32.
41. Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, Hammer RE, et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 1998;93:693-704. (Pubitemid 28257577)
42. Cummins CL, Volle DH, Zhang Y, McDonald JG, Sion B, Lefrancois-Martinez AM, et al. Liver X Receptors regulate adrenal cholesterol balance. J Clin Invest 2006;116:1902-12. (Pubitemid 44033314)
43. Volle DH, Lobaccaro JM. Role of the nuclear receptors for oxysterols LXRs in steroidogenic tissues: beyond the ''foie gras'', the steroids and sex? Mol Cell Endocrinol 2007;265-266:183-9.
44. Mouzat K, Volat F, Baron S, Alves G, Pommier AJ, Volle DH, et al. Absence of nuclear receptors for oxysterols liver X receptor induces ovarian hyperstimulation syndrome in mice. Endocrinology 2009;150:3369-75.
45. Dufour J, Pommier A, Alves G, De Boussac H, Lours-Calet C, Volle DH, et al. Lack of Liver X Receptors leads to cell proliferation in a model of mouse dorsal prostate epithelial cell. PLoS One 2013;8(3):e58876. http://dx.doi.org/ 10.1371/journal.pone.0058876.
46. Pommier AJ, Alves G, Viennois E, Bernard S, Communal Y, Sion B, et al. Liver X receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells. Oncogene 2010;29:2712-23.
47. Zelcer N, Hong C, Boyadjian R, Tontonoz P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 2009;325:100-4.
48. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 2000;14:2819-30.
49. Grefhorst A, Elzinga BM, Voshol PJ, Plosch T, Kok T, Bloks VW, et al. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem 2002;277:34182-90.
50. Joseph SB, Laffitte BA, Patel PH, Watson MA, Matsukuma KE, Walczak R, et al. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by Liver X Receptors. J Biol Chem 2002;277:11019-25. (Pubitemid 34952859)
51. Talukdar S, Hillgartner FB. The mechanism mediating the activation of acetylcoenzyme A carboxylase-alpha gene transcription by the liver X receptor agonist T0-901317. J Lipid Res 2006;47:2451-61. (Pubitemid 44936107)
52. Chu K, Miyazaki M, Man WC, Ntambi JM. Stearoyl-coenzyme A desaturase 1 deficiency protects against hypertriglyceridemia and increases plasma highdensity lipoprotein cholesterol induced by liver X receptor activation. Mol Cell Biol 2006;26:6786-98. (Pubitemid 44387629)
53. Cha JY, Repa JJ. The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR. J Biol Chem 2007;282:743-51.
54. Denechaud PD, Bossard P, Lobaccaro JM, Millatt L, Staels B, Girard J, et al. ChREBP, but not LXRs, is required for the induction of glucose-regulated genes in mouse liver. J Clin Invest 2008;118:956-64. (Pubitemid 351364603)
55. Ducheix S, Lobaccaro JM, Martin PG, Guillou H, Liver X. Receptor: an oxysterol sensor and a major player in the control of lipogenesis. Chem Phys Lipids 2011;164:500-14.
56. Fukuchi J, Kokontis JM, Hiipakka RA, Chuu CP, Liao S. Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells. Cancer Res 2004;64:7686-9. (Pubitemid 39446897)
57. De Boussac H, Pommier AJC, Dufour J, Trousson A, Caira F, Volle DH, et al. LXR, prostate cancer and cholesterol: the good, the bad and the ugly? Am J Cancer Res 2013;3:58-69.
58. Segawa T, Nau ME, Xu LL, Chilukuri RN, Makarem M, Zhang W, et al. Androgeninduced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells. Oncogene 2002;21:8749-58. (Pubitemid 36132396)
59. Swinnen JV, Esquenet M, Goossens K, Heyns W, Verhoeven G. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Cancer Res 1997;57:1086-90. (Pubitemid 27138606)
60. Swinnen JV, Heemers H, Deboel L, Foufelle F, Heyns W, Verhoeven G. Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway. Oncogene 2000;19:5173-81.
61. Zhuang L, Lin J, Lu ML, Solomon KR, Freeman MR. Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res 2002;62:2227-31. (Pubitemid 34411694)
62. Dufour J, Viennois E, De Boussac H, Baron S, Lobaccaro JM. Oxysterol receptors, AKT and prostate cancer. Curr Opin Pharmacol 2012;12:724-8.
63. Vendramini-Costa DB, Carvalho JE. Molecular link mechanisms between inflammation and cancer. Curr Pharm Des 2012;18:3831-52.
64. Baltaci S, Orhan D, Gogus C, Turkolmez K, Tulunay O, Gogus O. Inducible nitric oxide synthase expression in benign prostatic hyperplasia, low- and highgrade prostatic intraepithelial neoplasia and prostatic carcinoma. BJU Int 2001;88:100-3.
65. Steiner H, Godoy-Tundidor S, Rogatsch H, Berger AP, Fuchs D, Comuzzi B, et al. Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am J Pathol 2003;162:655-63. (Pubitemid 36267872)
66. Wegiel B, Bjartell A, Culig Z, Persson JL. Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. Int J Cancer 2008;122:1521-9. (Pubitemid 351294960)
67. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by Liver X Receptors. Nat Med 2003;9:213-9. (Pubitemid 36227724)
68. Viennois E, Mouzat K, Dufour J, Morel L, Lobaccaro JM, Baron S. Selective liver X receptor modulators (SLiMs): what use in human health. Mol Cell Endocrinol 2012;351:129-41.
69. Richards EJ, Elgin SC. Epigenetic codes for heterochromatin formation and silencing: rounding up the usual suspects. Cell 2002;108:489-500. (Pubitemid 34260874)
70. Abbas A, Gupta S. The role of histone deacetylases in prostate cancer. Epigenetics 2008;3:300-9.
71. Waltregny D, North B, Van Mellaert F, de Leval J, Verdin E, Castronovo V. Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells. Eur J Histochem 2004;48:273-90.
72. Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008;98:604-10. (Pubitemid 351214528)
73. Halkidou K, Cook S, Leung HY, Neal DE, Robson CN. Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. Eur Urol 2004;45:382-9. author reply 9. (Pubitemid 38221414)
74. Yang Y, Tse AK, Li P, Ma Q, Xiang S, Nicosia SV, et al. Inhibition of androgen receptor activity by histone deacetylase 4 through receptor SUMOylation. Oncogene 2011;30:2207-18.
75. Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, Sowa Y, et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 2006;281:13548-58. (Pubitemid 43855268)
76. Yamaguchi T, Cubizolles F, Zhang Y, Reichert N, Kohler H, Seiser C, et al. Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. Genes Dev 2010;24:455-69.
77. Annicotte JS, Iankova I, Miard S, Fritz V, Sarruf D, Abella A, et al. Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol Cell Biol 2006;26: 7561-74. (Pubitemid 44547706)
78. Hawk JD, Bookout AL, Poplawski SG, Bridi M, Rao AJ, Sulewski ME, et al. NR4A nuclear receptors support memory enhancement by histone deacetylase inhibitors. J Clin Invest 2012;122:3593-602.
79. Lazar MA. Nuclear receptor corepressors. Nucl Recept Signal 2003;1:e001.
80. Uehara Y, Miura S, von Eckardstein A, Abe S, Fujii A, Matsuo Y, et al. Unsaturated fatty acids suppress the expression of the ATP-binding cassette transporter G1 (ABCG1) and ABCA1 genes via an LXR/RXR responsive element. Atherosclerosis 2007;191:11-21. (Pubitemid 46227424)
81. Li X, Zhang S, Blander G, Tse JG, Krieger M, Guarente L. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol Cell 2007;28:91-106. (Pubitemid 47531974)
82. Ferrari A, Fiorino E, Giudici M, Gilardi F, Galmozzi A, Mitro N, et al. Linking epigenetics to lipid metabolism: focus on histone deacetylases. Mol Membr Biol 2012;29:257-66.
83. Chittur SV, Sangster-Guity N, McCormick PJ. Histone deacetylase inhibitors: a new mode for inhibition of cholesterol metabolism. BMC Genomics 2008;9:507.
84. Pipalia NH, Cosner CC, Huang A, Chatterjee A, Bourbon P, Farley N, et al. Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts. Proc Natl Acad Sci U S A 2011;108:5620-5.
85. Knutson SK, Chyla BJ, Amann JM, Bhaskara S, Huppert SS, Hiebert SW. Liverspecific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. EMBO J 2008;27:1017-28. (Pubitemid 351508160)
86. Li D, Wang X, Ren W, Ren J, Lan X, Wang F, et al. High expression of liver histone deacetylase 3 contributes to high-fat-diet-induced metabolic syndrome by suppressing the PPAR-gamma and LXR-alpha-pathways in E3 rats. Mol Cell Endocrinol 2011;344:69-80.
87. Funato H, Oda S, Yokofujita J, Igarashi H, Kuroda M. Fasting and high-fat diet alter histone deacetylase expression in the medial hypothalamus. PLoS One 2011;6:e18950.
88. Tang FY, Pai MH, Chiang EP. Consumption of high-fat diet induces tumor progression and epithelial-mesenchymal transition of colorectal cancer in a mouse xenograft model. J Nutr Biochem 2011;23:1302-13.
89. Dell'Aversana C, Lepore I, Altucci L. HDAC modulation and cell death in the clinic. Exp Cell Res 2012;318:1229-44.